Genmab A/S (GMAB) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GMAB Revenue Growth
GMAB Revenue Analysis (2013–2024)
As of May 6, 2026, Genmab A/S (GMAB) generated trailing twelve-month (TTM) revenue of $14.04 billion, reflecting significant decline in growth of -81.6% year-over-year. The most recent quarter (Q3 2025) recorded $1.02 billion in revenue, down 82.6% sequentially.
Looking at the longer-term picture, GMAB's 5-year compound annual growth rate (CAGR) stands at +32.0%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $21.53 billion in 2024, representing a new all-time high.
When compared to Healthcare sector peers including REGN (+5.9% YoY), SRPT (+47.1% YoY), and INCY (+21.5% YoY), GMAB has underperformed the peer group in terms of revenue growth. Compare GMAB vs REGN →
GMAB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GMABCurrent | $14.0B | -81.6% | +32.0% | 31.1% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% | |
 SRPT | $1.9B | +47.1% | +37.9% | 11.5% | |
 INCY | $5.1B | +21.5% | +14.0% | 26.1% | |
 EXEL | $2.3B | +3.3% | +18.6% | 37.6% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% |
GMAB Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $21.53B | +30.7% | $20.54B | 95.4% | $6.70B | 31.1% |
| 2023 | $16.47B | +13.6% | $16.25B | 98.6% | $5.32B | 32.3% |
| 2022 | $14.51B | +72.3% | $14.51B | 100.0% | $6.27B | 43.2% |
| 2021 | $8.42B | -16.8% | $8.42B | 100.0% | $2.95B | 35.1% |
| 2020 | $10.11B | +88.4% | $10.11B | 100.0% | $6.31B | 62.4% |
| 2019 | $5.37B | +77.4% | $5.37B | 100.0% | $2.64B | 49.2% |
| 2018 | $3.03B | +27.9% | $3.03B | 100.0% | $1.38B | 45.6% |
| 2017 | $2.37B | +30.2% | $2.37B | 100.0% | $1.34B | 56.8% |
| 2016 | $1.82B | +60.3% | $1.82B | 100.0% | $1.05B | 58.0% |
| 2015 | $1.13B | +33.2% | $1.13B | 100.0% | $730.4M | 64.5% |
Full GMAB Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See GMAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GMAB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GMAB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGMAB — Frequently Asked Questions
Quick answers to the most common questions about buying GMAB stock.
Is GMAB's revenue growth accelerating or slowing?
GMAB revenue declined -81.6% year-over-year, contrasting with the 5-year CAGR of +32.0%. TTM revenue fell to $14.0B. This reverses the prior growth trend.
What is GMAB's long-term revenue growth rate?
Genmab A/S's 5-year revenue CAGR of +32.0% reflects the variable expansion pattern. Current YoY growth of -81.6% is below this long-term average.
How is GMAB's revenue distributed by segment?
GMAB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.